Physician profile
May Dee Gemilo
NPI 1639645674
$3,763.13
in general payments reported to CMS, 2019-2025
17 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $352 · 2024: $2,060 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.14 |
| Education | $207.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $750.52 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $621.32 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $500.30 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $349.68 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $285.40 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $204.78 | 2023-2025 | Invega Sustenna, Invega Trinza, Risperdal |
| Supernus Pharmaceuticals, INC. | $178.05 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $160.40 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $156.64 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $141.88 | 2024-2025 | Cobenfy |
| Corium, LLC | $124.46 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $110.99 | 2024-2025 | Auvelity |
| Tris Pharma INC | $85.63 | 2024 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $31.47 | 2025 | Jornay Pm |
| Indivior INC. | $23.03 | 2024 | Sublocade |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $22.36 | 2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $16.22 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Dee Gemilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.